$FBRX
Forte Biosciences, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020018200 Filed on April 23, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q4
Revenue $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $760.0K $670.0K $3.120M
YoY Change -84.33% -84.94% -10.86%
% of Gross Profit
Research & Development $32.10M $3.141M $7.600M
YoY Change 168.17% -74.74% -51.34%
% of Gross Profit
Depreciation & Amortization $20.00K $57.00K $180.0K
YoY Change -90.48% -73.61% -14.29%
% of Gross Profit
Operating Expenses $32.10M $3.141M $10.71M
YoY Change 90.8% -81.39% -43.97%
Operating Profit
YoY Change
Interest Expense -$130.0K
YoY Change -56.67%
% of Operating Profit
Other Income/Expense, Net -$10.00K -$23.00K $0.00
YoY Change -96.66% -89.2%
Pretax Income -$34.76M -$2.050M -$10.58M
YoY Change 103.16% -88.0% -45.49%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$34.76M -$2.050M -$10.58M
YoY Change 5417.62% 73.0% -46.01%
Net Earnings / Revenue -105830.0%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.523M -$967.0K -$6.654M
COMMON SHARES
Basic Shares Outstanding 23.91M 23.90M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.70M $4.119M $19.77M
YoY Change -59.46% -94.86% -79.42%
Cash & Equivalents $27.70M $4.119M $6.939M
Short-Term Investments $0.00 $12.84M
Other Short-Term Assets $400.0K $300.0K $1.100M
YoY Change -91.11% -81.25% -35.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.10M $14.51M $22.96M
YoY Change -61.4% -82.24% -76.52%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $694.0K $1.689M
YoY Change -97.27% -81.8% -57.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Assets $200.0K $4.123M -$15.30M
YoY Change -98.39% -68.31% -386.86%
TOTAL ASSETS
Total Short-Term Assets $28.10M $14.51M $22.96M
Total Long-Term Assets $200.0K $4.123M -$15.30M
Total Assets $28.30M $18.63M $7.658M
YoY Change -66.8% -80.33% -92.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.600M $1.627M $1.569M
YoY Change 3.96% -41.89% -53.91%
Accrued Expenses $866.0K $6.030M $343.0K
YoY Change -91.66% -46.16% -97.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $4.700M
YoY Change 127.27%
Total Short-Term Liabilities $3.400M $12.64M $13.20M
YoY Change -80.36% -21.99% -20.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities $3.900M $81.00K
YoY Change -59.38% -96.32%
Total Long-Term Liabilities $0.00 $3.900M $81.00K
YoY Change -100.0% -88.43% -99.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.400M $12.64M $13.20M
Total Long-Term Liabilities $0.00 $3.900M $81.00K
Total Liabilities $3.400M $16.55M $17.31M
YoY Change -93.03% -66.83% -61.47%
SHAREHOLDERS EQUITY
Retained Earnings -$41.80M -$289.7M -$279.4M
YoY Change -83.29% 24.34% 29.42%
Common Stock $291.8M $290.2M
YoY Change 5.02% 5.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.88M -$6.772M -$4.769M
YoY Change
Total Liabilities & Shareholders Equity $28.30M $18.60M $28.16M
YoY Change -66.8% -80.36% -72.68%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income -$34.76M -$2.050M -$10.58M
YoY Change 5417.62% 73.0% -46.01%
Depreciation, Depletion And Amortization $20.00K $57.00K $180.0K
YoY Change -90.48% -73.61% -14.29%
Cash From Operating Activities -$4.010M -$2.865M -$10.71M
YoY Change -77.92% -83.8% -10.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $3.580M $17.27M
YoY Change -1378.57% 1304.07%
Cash From Investing Activities $3.580M $12.72M $17.27M
YoY Change -973.17% 108.66% 2172.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.00K
YoY Change -95.97%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 24.06M 45.00K -23.16M
YoY Change 271.87% -97.46% -181.21%
NET CHANGE
Cash From Operating Activities -4.010M -2.865M -10.71M
Cash From Investing Activities 3.580M 12.72M 17.27M
Cash From Financing Activities 24.06M 45.00K -23.16M
Net Change In Cash 23.63M -2.820M -16.60M
YoY Change -295.29% -71.27% -195.73%
FREE CASH FLOW
Cash From Operating Activities -$4.010M -$2.865M -$10.71M
Capital Expenditures $0.00
Free Cash Flow -$10.71M
YoY Change -6.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
277000
CY2020Q1 dei Entity File Number
EntityFileNumber
001-38052
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-213000
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q1 dei City Area Code
CityAreaCode
858
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Tocagen Inc
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 dei Trading Symbol
TradingSymbol
TOCA
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23914723
CY2020Q1 dei Local Phone Number
LocalPhoneNumber
412-8400
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4445 Eastgate Mall
CY2020Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001419041
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1243872
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23899261
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6030000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23899261
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
694000
CY2020Q1 us-gaap Assets
Assets
18632000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1627000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
14509000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5556000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4446000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-17084000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
16880000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1583000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23040951
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
23000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
291739000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-289680000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10280000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13204000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5242000
CY2020Q1 us-gaap Notes Payable Current
NotesPayableCurrent
4981000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3429000
CY2019Q4 us-gaap Assets
Assets
28160000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3218000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4744000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12638000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3912000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4027000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
81000
CY2020Q1 us-gaap Liabilities
Liabilities
16550000
CY2019Q4 us-gaap Liabilities
Liabilities
17312000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
290215000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-279400000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
10848000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28160000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3141000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12434000
CY2020Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
756000
CY2020Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-885000
CY2020Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-10000
CY2019Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
41000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
58145000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
248000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2000000
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1504000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10290000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17043000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23902889
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1514000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
41000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
44854000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1514000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2000000
CY2020Q1 us-gaap Depreciation
Depreciation
57000
CY2019Q1 us-gaap Depreciation
Depreciation
216000
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-916000
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
654000
CY2019Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
142000
CY2020Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-103000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
41000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-877000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-110000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1591000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-490000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
353000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2777000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-9000
CY2020Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
328000
CY2019Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
251000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7069000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17682000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
12722000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
27836000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21606000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12722000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6097000
CY2020Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
417000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
248000
CY2019Q1 toca Proceeds From Issuance Of Common Stock Under Atm Facility Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockUnderATMFacilityNetOfIssuanceCost
1522000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1770000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5246000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9815000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30998000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
101000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
606000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Significant estimates in the Company&#8217;s financial statements relate to clinical trial accruals and the valuation of equity awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results may differ from these estimates under different assumptions or conditions.</p>
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4864783
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4329408
CY2020Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q1 us-gaap Marketable Securities
MarketableSecurities
0
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
12825000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
10000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
12835000
CY2020Q1 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
0
CY2020Q1 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
405000
CY2019Q4 toca Accrued Clinical Trial Expenses Current
AccruedClinicalTrialExpensesCurrent
2404000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4106000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1116000
CY2020Q1 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
329000
CY2019Q4 toca Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
387000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
435000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
377000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
330000
CY2020Q1 us-gaap Interest Payable Current
InterestPayableCurrent
34000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
37000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
344000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
552000
CY2020Q1 us-gaap Restructuring Charges
RestructuringCharges
3500000
CY2020Q1 toca Severance And Other Related Termination Costs
SeveranceAndOtherRelatedTerminationCosts
3300000
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6611088
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1514000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2000000
CY2020Q1 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
The Company leases its office and laboratory space located in San Diego, California, for its corporate headquarters and research facility under an operating lease agreement (the Lease). The Lease commenced in March 2018.
CY2020Q1 toca Lessee Operating Lease Commenced Period
LesseeOperatingLeaseCommencedPeriod
2018-03
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P8Y
CY2020Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
the Company has one option to extend the Lease for a period of five additional years.
CY2020Q1 toca Number Of Options To Extend Lease
NumberOfOptionsToExtendLease
1
CY2020Q1 toca Lessee Operating Lease Additional Term Of Contract
LesseeOperatingLeaseAdditionalTermOfContract
P5Y
CY2020Q1 toca Lessee Operating Lease Tenant Improvement Allowance
LesseeOperatingLeaseTenantImprovementAllowance
1200000
CY2020Q1 toca Lessee Operating Lease Term Of Terminate
LesseeOperatingLeaseTermOfTerminate
P9M

Files In Submission

Name View Source Status
0001564590-20-018200-index-headers.html Edgar Link pending
0001564590-20-018200-index.html Edgar Link pending
0001564590-20-018200.txt Edgar Link pending
0001564590-20-018200-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
toca-10q_20200331.htm Edgar Link pending
toca-20200331.xml Edgar Link completed
toca-20200331.xsd Edgar Link pending
toca-20200331_cal.xml Edgar Link unprocessable
toca-20200331_def.xml Edgar Link unprocessable
toca-20200331_lab.xml Edgar Link unprocessable
toca-20200331_pre.xml Edgar Link unprocessable
toca-ex311_7.htm Edgar Link pending
toca-ex312_6.htm Edgar Link pending
toca-ex321_8.htm Edgar Link pending